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A vaccine that induces potent, broad and sustained cell-mediated immunity, resulting
in effective memory has the potential to restrict hepatitis C (HCV) virus infection. Early,
multi-functional CD4+ and CD8+ T cell responses against non-structural protein 3 (NS3)
have been associated with HCV clearance. Necrotic cells generate strong immune
responses and represent a major antigenic source used by dendritic cells (DC) for
processing and presentation, but there is conflicting evidence as to their immunogenicity
in vaccination. Immunization with DC loaded with viral antigens has been done in
the past, but to date the immunogenicity of live vs. necrotic DC vaccines has not
been investigated. We developed a DC2.4 cell line stably expressing HCV NS3, and
compared the NS3-specific responses of live vs. necrotic NS3 DC. Vaccination of mice
with necrotic NS3 DC increased the breadth of T-cell responses and enhanced the
production of IL-2, TNF-α, and IFN-γ by effector memory CD4+ and CD8+T cells,
compared to mice vaccinated with live NS3 DC. A single dose of necrotic NS3 DC
vaccine induced a greater influx and activation of cross-presenting CD11c+ CD8α+
DC and necrosis-sensing Clec9A+ DC in the draining lymph nodes. Furthermore,
using a hydrodynamic challenge model necrotic NS3 DC vaccination resulted in
enhanced clearance of NS3-positive hepatocytes from the livers of vaccinated mice.
Taken together, the data demonstrate that necrotic DC represent a novel and exciting
vaccination strategy capable of inducing broad and multifunctional T cell memory.
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INTRODUCTION
In the majority (70–80%) of infected individuals hepatitis C (HCV) infection leads to chronic
persistence of the virus, resulting in progressive, and often fatal liver disease and cancer. The
WHO recently reported that the rate of new HCV infections which is 1.75 million annually,
outpaces treatment and cure, setting back the goal to eliminate HCV by 2030 (Hill et al., 2017;
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WHO, 2017). HCV therapeutic cure, directly acting antivirals
(DAAs), does not prevent reinfection or eliminate residual cancer
risk. Therefore, the burden of chronic disease remains high.
An estimated 71 million people world-wide are chronically
infected with HCV, with as many as 50% unaware of their
infection status. Overall, it is estimated that only 20% of
infected individuals get diagnosed and only 2.9% are treated
with DAAs (Sandmann et al., 2019; WHO, 2019). Furthermore,
successful treatment with DAAs does not prevent re-infection
and increasing evidence suggests that DAA failure can lead
to the evolution of drug-resistant virus (Zeuzem et al.,
2017; Smith et al., 2019), suggesting that even the best
treatment options are unable to eradicate HCV. For this
reason, developing a HCV vaccine to complement therapy is
a public health priority in order to reduce the number of
new HCV infections.
Developing vaccines for persistent infections remains a
global challenge. A rational path for HCV vaccine design
is to achieve immune responses that mimic those elicited
during the resolution of acute HCV infection. Elimination
of acute HCV infection requires strong T cell-mediated
immunity (CMI) and broadly neutralising antibodies (NAb;
Lechner et al., 2000; Thimme et al., 2001, 2002; Bowen
and Walker, 2005). Development of vaccines that induce
NAb against HCV has proved elusive for several reasons,
mainly because current strategies fail to induce the extensive
somatic hypermutations required to generate broad NAb
(Edwards VC et al., 2012).
Human and chimpanzee studies have demonstrated
that broad and sustained HCV-specific CD8+ and CD4+
T cell responses against highly conserved non-structural
(NS) proteins, including NS3 result in clearance of acute
HCV (Liang, 2013). Antibody-mediated depletion of
CD8+ and CD4+ T cells in chimpanzees lead to virus
persistence (Grakoui et al., 2003; Shoukry et al., 2003).
Furthermore, T cell responses were responsible for the
persistent immunity after clearance of primary infection,
resulting in the reduction in the level and duration of
viremia after reinfection. Viral clearance was observed in
83% of reinfected patients, compared to 25% in primary
infection and was associated with a rapid T cell memory recall
(Osburn et al., 2010).
Therefore, it is becoming apparent that an effective HCV
vaccine strategy should induce strong CMI, targeting conserved
viral proteins, such as the NS proteins (Post et al., 2004; Grubor-
Bauk et al., 2015; Gummow et al., 2015; Wijesundara et al.,
2018; Mekonnen et al., 2019). Among the NS proteins, NS3
is an appropriate vaccine candidate as it is one of the most
genetically conserved HCV antigens across all genotypes, and
studies have shown a direct correlation between NS3-specific
immune responses and resolution of acute infection (Diepolder
et al., 1995, 1997; Schulze zur Wiesch et al., 2005).
Professional antigen presenting cells (APC), such as dendritic
cells (DC), process and present antigens to prime naïve
T lymphocytes, thus initiating adaptive immune responses
(Steinman, 2012). DC which are not directly infected with a
pathogen are capable of capturing, processing, and presenting
exogenous antigens (Ag) onto MHC class I molecules and
presenting these in a context of co-stimulatory molecules, a
process known as cross-presentation [reviewed in Joffre et al.
(2012)]. Cross presentation is essential for the initiation of Ag-
specific cytotoxic CD8+ T cell responses and can be a used as
a valuable tool to enhance vaccine responses. Although direct
presentation of epitopes results from endogenous expression
of the Ag in DC, as DC represent a rare population of
cells, it is likely that cross-presentation of exogenous Ag is
a more common pathway to induce immunity to vaccines
which do not directly target DC [reviewed in Heath et al.
(2004)]. Thus, successful vaccine strategies must target DC
directly and/or otherwise facilitate cross-presenting DC to
endocytose the immunogen.
In vivo, necrotic cells represent major sources of exogenous
Ag used by DCs for cross-presentation, as they release products
that influence Ag processing and presentation, such as damage
associated molecular patterns (DAMPs; Matzinger, 1994; Shi
et al., 2003; Gamrekelashvili et al., 2015). These include heat
shock proteins (HSP), uric acid, high mobility group box 1
protein (HMGB1), genomic DNA and F-actin, which act as
natural adjuvants (Sauter et al., 2000; Shi et al., 2003; Rock
et al., 2011; Ahrens et al., 2012). DAMPs bind to pathogen
recognition receptors (PRR) expressed in APC including DCs,
resulting in maturation and up-regulation of T cell costimulatory
molecules. These mature DC then migrate to draining lymph
nodes (LN) where they prime naïve T cells and initiate adaptive
T cell immunity.
In the past, studies have shown that freeze-thawed necrotic
tumor cells failed to induce Ag-specific CD8+ T cell responses,
despite the release of DAMPs (Scheffer et al., 2003; Casares
et al., 2005). However, more recently two cellular peptidases
released by necrotic cells, dipeptyl peptidase 3 (DPP-3),
and thimet oligopeptidase (TOP-1), have been shown to
control CD8+ T cell priming by proteasomal degradation
and thus block Ag cross-presentation (Gamrekelashvili
et al., 2013). Provided these peptidases were inactivated
by heat, trypsin treatment or gene knockdown they were
no longer able to degrade oligopeptides, resulting in T
cell activation.
The inference from these observations is that heat-induced
necrosis of antigen-positive cells will represent an important
component of an effective immunization strategy, and we
explored this possibility by immunization of mice with heat-
induced necrotic DCs expressing NS3.
We developed a mouse DC (DC2.4) cell line, stably expressing
HCV NS3 (genotype 1b). Vaccination with heat-induced necrotic
NS3 DC resulted in a greater influx of necrosis-sensing, cross-
presenting CD11c+ CD8α+ Clec9A+ DC in the LN draining the
site of injection at early time points post-vaccination compared to
mice vaccinated with live cells. This in turn, resulted in broader
and enhanced effector memory NS3-specific CD8+ and CD4+
T cell responses and accelerated NS3 antigen clearance from the
livers of vaccinated mice.
Collectively, our data suggest that necrotic cell vaccines
encoding HCV NS3 merit further study in the context of future
prophylactic HCV CMI-based vaccines.
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MATERIALS AND METHODS
Lentiviral Vector Construction and
Packaging
The codon optimized HCV genotype 1b (g1b) NS3 gene
was synthesized (Gene Art, Germany) and a third-generation
lentiviral vector encoding this protein was generated with
Gateway technology. In this system, expression of NS3 was under
the control of the EF-1α promoter and the marker gene (GFP)
was expressed from the encephalomyocarditis virus (EMCV)
internal ribosome entry site (IRES) [as described in Brown et al.
(2010)]. To generate a NS3 g1b lentiviral stock, HEK293T cells
were co-transfected with 12.5 µg of the NS3 transfer vector
(plvEIG), 7.5 µg of Gag/Pol (18.2), 6.25 µg of Rev (pRSV-
Rev), and 3.75 µg of Env (pCMV-VSV-G), using Lipofectamine
LTX reagent (Life Technologies, Australia) and Opti-MEM (Life
Technologies) reduced serum medium, in accordance with the
manufacturer’s protocol. The next day, the medium was replaced
with fresh RPMI and 48 h later the supernatant was collected,
filtered (0.45 µm), and used immediately or stored at−70◦C.
Lentiviral Transduction and
Establishment of NS3 DC2.4 Stable Cell
Line
Wild type DC2.4 and the NS3 DC2.4 expressing stable line were
cultured in RPMI 1640 medium supplemented with 100 U/ml
penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 10% FBS,
50 µM β-mercaptoethanol, 1 mM sodium pyruvate, and 10 mM
HEPES buffer. For lentiviral transduction of the wild type DC2.4
cell line, the medium from cells in a 6-well plate was replaced
with 3 ml of viral supernatant containing 8 µg/ml Polybrene.
NS3-GFP-positive DC2.4 cells were sorted by flow cytometry
(FACSAria; BD Biosciences, San Jose, CA, United States) until
purity reached 93.6%.
NS3 Immunofluorescence
To detect the expression NS3, wild type DC2.4 and NS3 DC2.4
cells were fixed with 4% formalin (Sigma Aldrich) for 20 min,
permeabilized with methanol at -20◦C then blocked in 2.5% BSA
(Sigma Aldrich) in PBS. The primary antibody, mouse anti-HCV
NS3 gt1b (Virostat) diluted in 1% BSA, 0.3% Triton X-100 (Sigma
Aldrich) in PBS, was added and incubated overnight at 4◦C. After
washing, the cells were then incubated for 1 h with fluorophore-
conjugated secondary antibody (1:300) anti-mouse – Cy5 (Life
Technologies). Cells were visualized by fluorescent microscopy
(Zeiss LSM-700).
Induction of Necrosis
Live NS3 DC2.4 cells were resuspended in sterile PBS at a
concentration of 1 × 107/ml. The cells were heated to 63◦C
for 30 min to induce necrosis. Necrosis was confirmed by
trypan blue staining.
Animals and Immunization
Female C57BL6 mice were obtained from the University of
Adelaide, Animal Laboratory Services or from the Animal
Resource Centre. Mice were housed in the Women’s and
Children’s Hospital (Adelaide, Australia) animal house and all
experimental protocols were approved by the Women’s and
Children’s Health Network and the University of Adelaide
Animal Ethics Committee. Animal experiments were carried out
according to the Australian Code of Practice for the care and use
of animals for scientific purposes. Female C57BL/6 (6–8 weeks
old) were immunized subcutaneously with 106 live or necrotic
wild type DC2.4 or NS3 DC2.4 cells in 100 µl of sterile PBS. In
the standard prime-boost regimen, mice were vaccinated with
the same dose at one-week intervals. 2 weeks after the final
vaccination, unless otherwise indicated, mice were euthanized,
and spleens were collected for analysis.
IFN-γ ELISpot Assay
NS3-specific cellular immune responses were assessed by IFN-
γ ELISpot assay as we described (Grubor-Bauk et al., 2015,
2019; Masavuli et al., 2019). Briefly, multiscreen-IP HTS plates
(Millipore) were coated with anti-mouse IFNγ (clone AN18,
MabTech) and secreted IFNγ was detected with anti-mouse
IFNγ -biotin (clone R4-6A2, MabTech), streptavidin-AP (Sigma
Aldrich) and SigmaFast BCIP/NBT (Sigma Aldrich). The 98-
peptide array spanning the entire NS3 protein (strain J4L6S,
genotype 1b) was obtained from the National Institutes for
Health Bio Defense and Emerging Infectious Research Resources
Repository, NIAID, National Institutes of Health United States.
Individual peptides overlap by 11–12 amino acids and detailed
information on their length and sequence is provided by BEI
Resources1. The NS3 peptides were divided into three pools,
each containing 29–31 individual peptides. Two C57BL/6 (H-
2b) epitopes, were described previously (Mikkelsen et al., 2011)
and were used as the immunodominant pool to stimulate
splenocytes in ELISpot and ICS. All peptides were used
at a final concentration of 4 µg/ml and splenocytes were
stimulated for 18–20 h at 37◦C. Splenocytes stimulated with
PHA (5 µg/ml) were used as a positive control and un-
stimulated splenocytes as a negative (background) control. The
spots were counted automatically using an ELISPOT reader
(AID GmbH, Germany).
Flow Cytometry
Multi-color intracellular cytokine staining (ICS) was performed
on splenocytes re-stimulated with immunodominant NS3
peptides for 12 h in the presence of protein transport inhibitor
(BD GolgiStopTM). Staining was performed with BD FACS
Cytofix/Cytoperm and BD anti-mouse antibodies (CD3-PercP-
Cy5.5, CD8-APC-Cy7, CD44-APC, IL-2-FITC, IFNγ –PeCy7,
TNFα-PE, and BD Biosciences). The cells were analyzed on a
BD FACS Canto II flow cytometer using the gating strategy we
described previously (Gargett et al., 2014; Gummow et al., 2015).
Briefly, splenocytes were gated on the lymphocyte population,
followed by doublet discrimination and then gated on CD3+,
CD44high cells and finally CD4+ or CD8+ cells to assess the
frequency effector memory CD4+ or CD8+ T cells. Within the
CD44high CD4+ or CD44high CD8+ T cell populations single
1http://www.beiresources.org/Catalog/BEIPeptideArrays/NR-3742.aspx
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(IFNγ, TNFα, or IL-2), double (IFNγ and TNFα), and triple
cytokine positive cells were identified (IFNγ, TNFα, and IL-2).
Dendritic cells staining was performed on cell suspensions
obtained from the axillary draining LN using the following
antibodies CD3-PerCP-Cy5, CD8a-APC-Cy7 (BD Bioscience),
CD11c-PeCy7, CD86-PE, MHCII-FITC (EBioscience), and
Clec9A-PE antibody from Miltenyi Biotec and analyzed as we
described previously (Gargett et al., 2014; Garrod et al., 2014).
Briefly, purified lymphocytes cells were gated on CD3− cells
(non T cells), and then on CD11chigh MHCII+ cells (DC),
CD11chigh MHCII+ CD8a+ cells (cross-presenting CD8a+ DC)
and CD11chigh MHCII+ CD8a+ Clec9A+ (necrosis-sensing
Clec9a+ DC) or CD11chigh MHCII+ CD8a+ CD86+ (activated
cross presenting CD8a DC). The results were analyzed with
FlowJo X.0.7 software (Ashland, OR, United States).
T Cell Proliferation Studies
Proliferation of CD8+ and CD4+ T cells was assessed by flow
cytometry after CFSE staining. Splenocytes from vaccinated
mice were labeled with 10 µM CFSE (CellTrace CFSE Cell
Proliferation Kit protocol; Life Technologies) as per the
manufacturer’s instructions and stimulated in vitro with 4 µg/mL
immunodominant NS3 peptides or left unstimulated. After
5 days, CFSE-labeled splenocytes were surface stained with CD3-
PerCP-Cy5.5, CD4-eFluor450, and CD8-APC-Cy7 (all from
eBioscience), followed immediately by Hoechst staining prior
to analysis by flow cytometry. Proliferative responses were
measured by CFSE dilution assay of cell proliferation as we
described previously (Gargett et al., 2014; Garrod et al., 2014;
Gummow et al., 2015). The results were analyzed with FlowJo
X.0.7 software (Ashland, OR, United States).
Mouse Hydrodynamic Challenge
Female C57BL/6 mice were vaccinated with 106 live or necrotic
NS3 DC2.4 s.c. (standard prime-protocol) and challenged
2 weeks later by hydrodynamic injection of 20 µg of pNFS
plasmid in TransIT-QR HD delivery solution (Mirus) in a volume
of 1/10 body weight. Unvaccinated mice were challenged as a
control. Hydrodynamic injection was performed as we described
(Yu et al., 2014). In the pNFS plasmid used to challenge mice,
NS3/4A protein expression is controlled by the mouse albumin
promoter/α-fetoprotein enhancer ensuring hepatocyte-specific
expression of HCV NS3/4A. Introns 1 and 2 were included
to optimize expression. Secreted alkaline phosphatase (SEAP)
is encoded as a fusion protein, preceded by the FMDV2A
protease which is designed to self-cleave and release SEAP
co-translationally. Any mouse which failed to receive the full
challenge volume was excluded from further analysis. Serum
samples were collected from the challenged mice at different
time-points and levels of SEAP were measured using the
Phospha-light kit (Applied Biosystems) in 96 well flat bottom
white microplates (GreinerBioOne; Yu et al., 2014).
Statistical Analysis
Data are presented as means ± the standard errors of the mean
(SEM). Statistical methods including unpaired Mann–Whitney
test, Kruskal–Wallis H test and log-rank (Mantel-Cox) test were
used as necessary, with P ≤ 0.05 (∗), P ≤ 0.01 (∗∗), and
P ≤ 0.001 (∗∗∗) considered significant. Analysis was performed
using GraphPad Prism version 6.00 for Windows (GraphPad
Software, La Jolla, CA, United States) with assistance from Dr.
Stuart Howell from the Data Analysis and Management Centre,
University of Adelaide.
RESULTS
Necrotic NS3 DC2.4 Are More
Immunogenic Than Live NS3 DC2.4 and
Increase the Breadth of NS3-Specific T
Cell Responses in Vaccinated Mice
Due to their central role in T cell activation, vaccination
strategies involving DCs have been used in the past in patients
suffering from cancer or from viral infections such as HCV
and human immunodeficiency virus (Lu et al., 2004; Gowans
et al., 2010; Palucka and Banchereau, 2012). In the case
of HCV, overexpression of structural gene products such as
core and envelope has been reported to interfere with the
immunostimulatory functions of DC, but overexpression of NS3
had no effect on DC maturation (Sarobe et al., 2003). We
transduced murine DC2.4 cells with a lentivirus encoding codon
optimized NS3 (genotype 1b: gtb1b), under the control of the
EF-1α promoter, and GFP controlled by the IRES from EMCV
(Supplementary Figure 1A). Constitutive and stable expression
of NS3 was shown by immunofluorescence, using untransduced,
wild type, DC2.4 cells as negative controls (Supplementary
Figure 1B). Using fluorescence-activated cell sorting, NS3
positive DC2.4 cells were purified and sorted on the basis of their
GFP expression. The final purity of NS3 DC2.4 cells was 93.6%,
as confirmed by flow cytometry (Supplementary Figure 1C).
Similar to the overexpression of NS3 in DC derived from BALB/c
and C57BL/6 mice (Zabaleta et al., 2008), overexpression of NS3
in DC2.4 had no significant effect on the expression of CD80,
CD86, and CD11c, when compared to wild type DC2.4 cells
(Supplementary Figure 1D). To induce heat-shock necrosis NS3
DC2.4 cells were heated to 63◦C for 30 min and necrosis was
confirmed by trypan blue staining.
To analyze the immunogenicity of NS3 DC2.4 in vivo,
6–8 week old female C57BL/6 mice were immunized
subcutaneously (s.c.) with 106 live or necrotic NS3 DC, in
a prime-boost regimen. Wild-type (WT) DC2.4 cells that do not
express HCV NS3 antigen, were used as controls. Subcutaneous
injection was chosen as the route of vaccination as an earlier
study showed that live DC2.4 injected by this route migrated to
regional LN and interacted with naïve T cells to prime Ag-specific
immune response (Okada et al., 2001). This permitted a direct
comparison of the immunogenicity of “standard” migrating live
DC2.4 and necrotic DC2.4, expected to remain in situ at the site
of injection. The magnitude and breadth of the NS3-specific T
cell responses were analyzed by IFN-γ ELISpot at 2 (Figure 1A)
and 4 (Figure 1B) weeks post-boost. ELISpots were performed
by stimulating splenocytes with 3 overlapping peptide pools
(approx. 30, 11–15mer peptides per pool) spanning the entire
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FIGURE 1 | Necrotic NS3 DC2.4 cells are more immunogenic than live NS3 DC2.4 cells in C57BL/6 mice. Mice were vaccinated twice, at 2 week intervals with 106
necrotic or live NS3 DC2.4 (A) 2 or (B) 4 weeks after the last dose. NS3-specific T cell responses were measured by IFN-γ production in an ELISpot assay.
Splenocytes from vaccinated animals were re-stimulated with 3 different pools of overlapping peptides covering the complete NS3 protein (pools 1–3), or with a pool
of H2b (C57BL/6) T cell NS3 immunodominant epitopes. Plots are representative of two independent experiments (n = 7/group). Data represent mean SFU per 106
splenocytes (±SEM). ∗p < 0.05, ∗∗p < 0.01, and ∗∗p < 0.001 (Kruskal–Wallis H test).
NS3 protein, and an additional pool containing only C57BL/6
immunodominant T cell peptides (which are otherwise present
in Pools 1 and 3; Mikkelsen et al., 2011). Mice vaccinated with
necrotic NS3 DC2.4 generated significantly higher NS3-specific
IFN-γ responses than those vaccinated with live NS3 DC2.4
across all pools, at both time points (Figure 1). At 2 weeks
post-vaccination the magnitude of the NS3-specific effector
response induced by necrotic NS3 DC2.4 was increased by
5∼fold for Pool 1 (mean 256 SFU vs 55 SFU), 3∼fold for Pool
2 (mean 288 SFU vs 100 SFU), ∼3 fold for Pool 3 (mean 225
SFU vs 80 SFU), and almost 5 fold for the immunodominant
(ID) pool (mean 332 SFU vs 72 SFU; Figure 1A). As expected,
control WT DC2.4 vaccination, necrotic or live, did not elicit any
NS3-specific T cell responses. At 4 weeks post-immunization,
vaccination with necrotic DC2.4 induced a significantly higher
NS3-specific response that was increased by approximately ∼2
fold for all peptide pools (Pool 1 mean 196 SFU vs 100 SFU; Pool
2: mean 295 SFU vs 141 SFU; Pool 3 mean 343 SFU vs 145 SFU;
and ID pool 396 SFU vs 176 SFU) compared with the live DC2.4
cells (Figure 1B). Importantly as Pool 2 contains none of the
immunodominant NS3 peptides and as the responses from mice
vaccinated with live NS3 DC2.4 were significantly lower than
the responses from mice vaccinated with necrotic NS3 DC2.4,
this represents a distinct broadening of the immune response
to non-dominant NS3 epitopes. Responses generated against
the previously identified immunodominant T cell epitopes
were enhanced and significantly higher at 2 and 4 weeks post
vaccination in mice vaccinated with necrotic NS3 DC2.4 cells
than those vaccinated with live NS3 DC2.4 (Mikkelsen et al.,
2011). This is an important finding as strong HCV-specific T-cell
responses against multiple epitopes are associated with the onset
of viral clearance (Thimme et al., 2002).
Immunization With Necrotic NS3 DC2.4
Cells Induces Multifunctional T Cell
Responses and Enhances T Cell
Proliferation
Multifunctional T cells, simultaneously secreting IL-2, TNF-α,
and IFN-γ, have been associated with the control of numerous
viral infections, including HCV. Studies of HCV-infected patients
proposed the importance of multifunctional CD8+ T cells in
effective control of HCV replication and have been suggested
to represent an important correlate of viral clearance in acute
phase patients (Shoukry et al., 2003; Badr et al., 2008). Therefore
to assess these responses, splenocytes from vaccinated C57BL/6
mice were harvested 2 weeks post-vaccination, stimulated in vitro
with the immunodominant NS3 epitopes and the functional
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characteristics of the effector memory CD3+ CD44high CD8+ and
CD3+ CD44high CD4+ T cells assessed by ICS (Supplementary
Figure 2). CD8+ CD44high effector memory T cells responded
to re-stimulation by producing IL-2, TNF-α, or IFN-γ, but
there was no significant difference in the frequency of single
cytokine producing cells between the mice that received live or
necrotic NS3 DC2.4 (Figure 2A). However, in mice vaccinated
with necrotic NS3 DC2.4, cytokine secreting CD8+ CD44high+
T cells produced significantly more IFN-γ and TNF-α, but
not IL-2 as shown by the mean fluorescence intensity (MFI;
Figure 2B). Mice vaccinated with necrotic NS3 DC2.4 also
showed a significant increase in the frequency (∼2-fold) of
CD8+ CD44high T cells simultaneously producing IFN-γ and
TNF-α (mean percentage 2.94 vs 1.4) and IL-2 and IFN-
γ (mean percentage 2.51 vs 1.04; Figure 2C). There was
also a trend toward an increase in the frequency of rare,
multifunctional CD8+ CD44high T cells that produced TNF-α,
IFN-γ, and IL-2 simultaneously (mean percentage 1.93.vs 1.64;
Figure 2D).
Next, we examined the cytokine responses of CD4+ CD44high
effector memory T cells following vaccination with live or
necrotic NS3 DC2.4 cells. Interestingly, vaccination with live
rather than necrotic NS3 DC2.4 generated an increased frequency
of CD4+ CD44high T cells, secreting single cytokines IFN-
γ, IL-2, or TNF-α (Figure 3A) and double cytokines IL-
2/IFN-γ and IL-2/TNF-α (Figure 3B). However, there was no
difference in the frequency of triple cytokine producing CD4+
CD44high T cells between mice that received live or necrotic
NS3 DC2.4 (Figure 3D). Nevertheless, although they were less
frequent, cytokine producing CD4+ CD44high T cells from mice
immunized with necrotic NS3 DC2.4 cells produced significantly
higher levels of IFN-γ, IL-2, and TNF-α as determined by ICS
(Figure 3C). This indicates that these cells were more functionally
active, as these CD4+ T cell-cytokines drive the maturation of
protective CD8 memory responses (Shoukry et al., 2003).
Robust T cell proliferation upon re-stimulation with the
vaccine immunogen is the aim of any vaccine strategy. Therefore,
to examine the proliferative capacity of NS3-specific T cells,
induced in response to immunization with live or necrotic NS3
DC2.4 cells, splenocytes from vaccinated mice were re-stimulated
with the immunodominant NS3 peptides in an ex vivo CFSE
proliferation assay (Supplementary Figure 3). Mice vaccinated
with necrotic NS3 DC2.4 cells showed a significant increase in
the proliferation of NS3-specific CD8+ T-cells (mean percentage
FIGURE 2 | Cytokine profile of NS3-specific effector memory CD8+ T cells in vaccinated mice. Splenocytes from C57BL/6 mice (n = 7/group) vaccinated with 106
live or necrotic NS3 DC2.4 cells were harvested 14 days post vaccination and restimulated with immunodominant NS3 epitopes. Intracellular cytokine staining was
performed (Supplementary Figure 2) to assess the frequency of (A) CD3+ CD8+ T CD44 high effector memory T cells that are single cytokine producers of IFN-γ
or IL-2 or TNF-α, (B) The MFI of IFN-γ, IL-2, and TNF-α producing NS3 specific CD3+ CD8+ T CD44high T cells; (C) Frequency of CD8+ CD44high effector memory
T cells that are double cytokine producers of IFN-γ/TNF-α or IL-2/IFN-γ or IL-2-TNF-α (D) IFN-γ/TNF-α/IL-2 triple-positive CD8+ CD44 high effector memory T cells.
Plots are representative of two independent experiments. Data show mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 (Mann–Whitney test).
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FIGURE 3 | Cytokine profile of NS3-specific CD4+ T cells in vaccinated mice. Splenocytes from C57BL/6 mice, vaccinated with 106 live or necrotic NS3 DC2.4 cells
were harvested 14 days post-vaccination and restimulated with immunodominant NS3 epitopes. Intracellular cytokine staining was performed (Supplementary
Figure 2) to assess the frequency of (A) CD3+ CD4+ T CD44high effector memory T cells that are single cytokine producers of IFN-γ or IL-2 or TNF-α,
(B) Frequency of CD4+ CD44high effector memory T cells that are double cytokine producers of IFN-γ/TNF-α or IL-2/IFN-γ or IL-2-TNF-α. (C) The MFI of IFN-γ, IL-2
and TNF-α of NS3 specific CD3+ CD4+ T CD44high T cells; (D) IFN-γ/TNF-α/IL-2 triple-positive CD4+ CD44high effector memory T cells. Plots are representative of
two independent experiments (n = 7/group). Data show mean ± SEM. ∗p < 0.05, ∗∗p < 0.01 (Mann–Whitney test).
0.88%) compared to mice that received live NS3 DC2.4 (mean
percentage 0.3%; Figure 4), a vaccination outcome essential for
effector T-cell function. Proliferation of CD4+ T cells from
mice vaccinated with necrotic DC2.4 cells was 4-fold higher
than that observed for CD4+ T cells from mice vaccinated
with live NS3 DC2.4 (mean percentage 2% vs 0.5%; Figure 4).
This is a crucial finding, as previous studies have found that
a strong and sustained NS3-specific CD4+ T cell proliferative
response is an important correlate of the clearance of acute
infection and in preventing the progression to chronic HCV
infection (Diepolder et al., 1995, 1997; Thimme et al., 2002;
Schulze Zur Wiesch et al., 2012).
Immunization With Necrotic NS3 DC2.4
Induces Greater Numbers and Activation
of Cross-Presenting CD8a+ DCs in
Draining Lymph Nodes
Successful delivery of antigens to DC in vivo is crucial for
effective CMI, as DC are necessary to activate naive T cells in
secondary lymphoid organs (Masson et al., 2008; Pulendran and
Ahmed, 2011). Therefore, to assess the mechanism by which
T-cell responses were increased by vaccination with necrotic NS3
DC2.4, we investigated the kinetics of DC accumulation and
activation in the LN draining the site of immunisation (DLN).
We focused on CD8α+ DCs, due to their ability to cross-present
Ag and prime CD8+ T cells (Shortman and Heath, 2010). Female
C57BL/6 mice were vaccinated s.c. with a single dose of 106
live or necrotic NS3 DC2.4 cells and axillary LNs were collected
2, 3, 5-, and 7-days post-vaccination. DC subpopulations were
identified as CD3e−, CD11chigh MHCII+ and CD8a+ as we
described previously (Supplementary Figure 4; Gargett et al.,
2014; Garrod et al., 2014). The absolute numbers of cross-
presenting CD8α+ CD11chigh DC in DLN increased over time
in response to vaccination in both groups (Figure 5A). On
days 5 and 7 post-vaccination, mice that received necrotic NS3
DC2.4 cells had significantly greater numbers of cross-presenting
CD8α+ CD11chigh DC than mice that received live NS3 DC2.4
(d5: mean 10500 vs 7500 cells; d7: mean 17,300 vs 10,800
cells). The activation status of LN-resident DC, analyzed by
CD86 expression, showed that mice vaccinated with necrotic NS3
DC2.4 cells displayed a significant increase in the frequency of
activated CD8α+CD11chigh DC compared with mice vaccinated
with live NS3 DC2.4 (Figure 5B).
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FIGURE 4 | Vaccination with necrotic NS3 DC2.4 enhances ex vivo T-cell
proliferation in vaccinated mice. Proliferation of CD4+ and CD8+ T cells
harvested from splenocytes of mice vaccinated with live or necrotic NS3
DC2.4 was assessed by CFSE staining and then analyzed by flow cytometry
(Supplementary Figure 3). Proliferative responses were measured by CFSE
dilution. The graph demonstrates the percent proliferation of CD3+ CD4+ T
cells and CD3+ CD8+T cells. Plots are representative of two independent
experiments (n = 7/group). Data show mean ± SEM of seven samples.
**p < 0.01 (Mann–Whitney test).
The C-type lectin receptor, Clec9A, is expressed by CD8α+
DC and links the recognition of necrotic cells to the subsequent
cross-presentation of dead-cell-associated antigens to T cells,
thus inducing efficient CD4+ and CD8+ T cell responses in vivo
(Sancho et al., 2008, 2009; Idoyaga et al., 2011; Zhang et al.,
2012). Consequently, we assessed absolute numbers of Clec9A+
CD8α+ CD11chigh DC in DLN post vaccination. The numbers of
Clec9A+ DC increased 2 days post vaccination in both groups
of vaccinated mice (Figure 5C). However, on days 5 and 7
post-vaccination, mice that received necrotic NS3 DC2.4 cells
generated significantly greater numbers of Clec9A+ CD11chigh
CD8α+ DC in DLN, compared to mice vaccinated with live
NS3 DC2.4 (Figure 5C). This indicates that the mechanism
of enhanced immunogenicity of necrotic NS3 DC2.4 may be
attributed to an increased influx of cross-presenting CD8α+
DC and necrosis sensing Clec9A+ CD8α+ DC, as well as an
increase in activation, consistent with necrosis-enhanced cross-
presentation of antigen.
Vaccination With Necrotic NS3 DC2.4
Accelerates Clearance of NS3 Antigens
From Livers of Vaccinated Mice
As liver is the main target organ for HCV infection, we
examined whether immunization with necrotic NS3 DC2.4
results in enhanced clearance of HCV antigens from the liver.
We previously developed a challenge mouse model (Yu et al.,
2014), where DNA encoding wild type HCV NS3/4A antigens
is delivered to mouse hepatocytes via hydrodynamic intravenous
injection into the tail vein. As the DNA also encodes SEAP,
SEAP levels in mouse serum act as a surrogate marker for
intrahepatic expression of NS3/4A proteins in a minimally-
invasive manner. Therefore, successful vaccination of mice
should result in accelerated clearance of HCV antigen-positive
hepatocytes, reflected by the accelerated clearance of SEAP
from sera.
Two groups of C57BL/6 mice were vaccinated prime-boost
(s.c.) with 106 live or necrotic NS3 DC2.4 cells and were
challenged 10 days after the second dose with 20 µg of NS3/4A-
SEAP DNA via hydrodynamic delivery. Control unvaccinated
mice were also challenged. Mice vaccinated with live or necrotic
NS3 DC2.4 cells had significantly lower levels of secreted SEAP,
when compared to unvaccinated controls (Figure 6A). There
was no significant difference in levels of SEAP between the two
vaccinated groups. However, at later time points after challenge
(days 18–34) mice that received necrotic NS3 DC2.4 cleared
SEAP (and thus NS3 antigens from the liver) at a faster rate than
FIGURE 5 | DC kinetics in DLN post vaccination. Axillary lymph nodes were harvested on days 2, 3, 5, and 7 after a single (s.c.) vaccination with 106 live or necrotic
NS3 DC2.4 cells CD3-, CD11chigh, MHCII+ cells were identified and assessed for CD8α, CD86, and Clec9A expression. (A) Absolute numbers of CD11chigh MHC
II+ CD8α+ DC. (B) Percentage of CD86 expressing CD11chigh MHC II+ CD8α+ DC. (C) Absolute numbers of Clec9A + CD11chigh CD8α+ DC. Plots are
representative of two independent experiments (n = 5/group/time point). Data show mean ± SEM. ∗p < 0.05, ∗∗p < 0.01 (Mann–Whitney test).
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FIGURE 6 | Vaccination with necrotic NS3 DC2.4 results in accelerated clearance of NS3 antigens from livers of challenged mice. Groups of C57BL6 mice were
vaccinated with 106 live (n = 15) or necrotic (n = 14) NS3 DC2.4 cells. Unvaccinated mice were used as controls (n = 17). 2 weeks post-vaccination, all groups were
challenged with 20 µg NS3/4A pNFS by hydrodynamic injection. (A) SEAP levels were measured at 3 day intervals post-challenge in the sera of individual mice
(Mann–Whitney test). (B) Clearance of NS3/4A antigens from the livers of challenged mice was accelerated in mice vaccinated with necrotic NS3 DC2.4 when
compared to mice vaccinated with live NS3 DC2.4 and unvaccinated controls [Log-rank (Mantel-Cox) test]. Plots are representative of two independent experiments.
Data show mean ± SEM. *p < 0.05, **p < 0.01.
mice that were vaccinated with live NS3 DC2.4 (Figure 6B). The
clearance rate, determined as a SEAP level equivalent to or lower
than background levels of SEAP in serum, was enhanced in mice
that received necrotic NS3 DC2.4 as on day 25, 54% (8 of 14) of
mice cleared SEAP to background levels, compared to only 25%
(4 of 15) of mice vaccinated with live NS3 DC2.4 and 5% (3 of 17)
of unvaccinated controls (Figure 6B). On day 34 post challenge,
SEAP was undetected in 93% (13 of 14) of mice from the necrotic
NS3 DC2.4 group, compared to 70% (10 of 15) of mice vaccinated
with live NS3 DC2.4 and 67% (12 of 17) of unvaccinated controls
(Figure 6B). Vaccination with necrotic NS3 DC2.4 resulted in
faster clearance rate of SEAP at later time points post-challenge,
indicating that vaccination with necrotic NS3 DC2.4 resulted in
enhanced elimination of NS3-positive hepatocytes.
DISCUSSION
Despite the therapeutic cure for chronic HCV infection, a
prophylactic vaccine is necessary in order to control new HCV
infections and to decrease the burden of HCV-induced liver
diseases, such as hepatocellular carcinoma and liver cirrhosis.
An effective CMI, necessary for HCV clearance is typically of
high magnitude, broad, polyfunctional, and sustained (Walker,
2010). In mice, CD8α+DCs are the main DC subset responsible
for priming CMI, due to their intrinsic ability to cross-present
antigens to naïve CD8+ T cells (Belz et al., 2004; Schnorrer et al.,
2006; Dudziak et al., 2007). Therefore, CD8α+ DCs have been the
target of many vaccine strategies, including the use of monoclonal
antibodies specific for CD8α+ DCs to deliver Ag (Caminschi
et al., 2008; Idoyaga et al., 2011; Lahoud et al., 2011).
In the past, immunization with ex vivo antigen loaded
DC, has been used to induce immune responses against
various exogenous antigens as well as tumor-associated antigens
[reviewed in Palucka and Banchereau (2012)]. We took a different
approach and investigated the immunogenicity of Ag positive
necrotic DC as a novel vaccine strategy, since necrosis is known
to promote antigen uptake, cross-presentation and activate DCs
(Matzinger, 1994; Shi et al., 2003; Gamrekelashvili et al., 2015).
We examined the immunogenicity of the murine DC2.4 cell line,
stably transduced to express the HCV NS3 (gt1b) protein as a
necrotic or live vaccine. Expression of NS3 in DC2.4 cell line
had no effect on their phenotype, consistent with previous reports
(Sarobe et al., 2003; Li et al., 2006; Zabaleta et al., 2008).
Following immunization with live or necrotic NS3 DC2.4
we focused our investigation primarily on the features of T
cell responses that have been found to correlate with clearance
of acute HCV infection in humans, including the breadth and
magnitude, the proliferative capacity and multifunctionality of
NS3-specific T cell responses (Diepolder et al., 1995; Missale
et al., 1996). Mice vaccinated with necrotic DC2.4 were able
to mount a much stronger and broader NS3-specific IFN-γ
responses, directed against a greater number of different NS3
epitopes spanning the entire protein, than that observed in mice
that received live NS3 DC2.4 cells, when measured 2 or 4 weeks
after vaccination. In the context of a prophylactic HCV vaccine,
the generation of such a strong and broad antiviral response is
important as efficient production of IFN-γ has been associated
with a large reduction in the viral load during acute infection
in humans (Thimme et al., 2001). Additionally, analysis of the
cytokine profile revealed that NS3-specific CD8+ and CD4+
effector memory T cells were able to produce IFN-γ, IL-2, and
TNF-α in response to NS3 peptide stimulation. Vaccination
with necrotic NS3 DC2.4 induced a greater frequency of
multifunctional CD8+ T cells that secreted higher levels of all
three cytokines, compared to vaccination with live NS3 DC2.4.
Apart from their capacity for cytokine production, cytotoxic
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T cells are important for efficient virus control. Therefore the
induction of a robust, multifunctional, CD8+ T cell response by
necrotic NS3 DC2.4 vaccination is extremely encouraging as the
appearance of such cells is associated with spontaneous recovery
from acute HCV infection [reviewed by Sung et al. (2014)].
We also showed that vaccination with necrotic NS3 DC2.4
induced effector memory NS3-specific CD4+ T cells that secreted
significantly higher levels of IFN-γ, IL-2, and TNF-α, suggesting
that even though they were less frequent they were functionally
more active. Especially important, as a functional CD4+ T cell
response represents a key factor dictating the outcome of viral
infection, as viral clearance is associated with rapid recall of
memory T-cell responses (Shoukry et al., 2003) which depends
on critical CD4 T-cell help to maintain T-cell memory (Grakoui
et al., 2003) and promote maturation of memory CD8+ responses
(Zajac et al., 1998). Vaccination with necrotic NS3 DC2.4 also
resulted in enhanced (ex vivo) proliferation of NS3-specific
CD8+ and CD4+ T cells compared to vaccination with live NS3
DC2.4. Whereas vaccination with live NS3 DC2.4 induced similar
levels of proliferation for CD8+ and CD4+ T cells, vaccination
with necrotic NS3 DC2.4 greatly increased the proliferation of
CD4+ T cells. This is significant as previous studies have shown
that an ongoing strong CD4+ proliferative response, especially
that directed against NS3, was an important correlate of viral
control and clearance, whereas comparable responses are absent
in chronically evolving infection (Diepolder et al., 1995; Missale
et al., 1996; Thimme et al., 2001).
Our study also provided information on the possible identity
of DC responsible for enhanced T cell responses in vivo, as there
are no direct means by which genotype 1b NS3 antigen can
be detected in cross-presenting DC. Vaccination with necrotic
NS3 DC2.4 resulted in increased numbers of activated CD8α+
CD11chigh DCs in the DLN, a cell population that is essential for
cross-presentation of antigens derived from dying cells to naive
CD8+ T cells. It is likely that this effect is mediated through
Clec9A signaling via F-actin (Zhang et al., 2012) as necrotic NS3
DC2.4 vaccination increased the absolute numbers of Clec9A+
CD8α+ CD11chigh DCs in DLN. Targeting antigens to Clec9A–
expressing DC is a potential mechanism to enhance vaccine
efficiency, as targeting Clec9A DC with a monoclonal antibody
induced strong HIV gag-specific Th1 and CD8+ T-cell responses
in mice (Idoyaga et al., 2011).
To examine the ability of vaccine-induced immune cells
to migrate to the liver, we performed experiments to address
the in vivo function of the immune response. We used a
hydrodynamic challenge model, developed in our laboratory that
results in NS3/4A expression in hepatocytes and secretion of
SEAP in serum (Yu et al., 2014). As expected, vaccination with
live and necrotic NS3 DC2.4 resulted in lower SEAP levels in
serum, compared to that of unvaccinated controls. At later time
points necrotic NS3 DC2.4 vaccination resulted in accelerated
NS3 clearance from the liver. It is plausible that CTLs primed by
necrotic cell vaccination migrated to the liver and cleared NS3-
expressing hepatocytes more efficiently. A major limitation of
this model is that it is necessary to target 5–10% of hepatocytes
to detect SEAP in serum. Thus, no HCV vaccine candidate to
date, in our laboratory, has been able to completely prevent
NS3/4A antigen expression in hepatocytes. In contrast, during
natural HCV infection, it is likely that only a few cells get infected
initially. Nevertheless, due to the lack of available HCV challenge
options in mice, it is still a viable model to assess the rate
of clearance of viral antigens, particularly as the migration of
immune cells to the liver of an infected individual is likely to be
vital in the outcome of infection with HCV, in order to tip the
balance in favor of the host.
Many factors influence the cross-presenting efficiency of
DC, which is not only dependent on the ability to capture
Ag, but is also affected by critical factors such as the
form and quantity of Ag available, the route of Ag uptake,
Ag degradation in endosomal-lysosomal compartments and
Ag entry into the major histocompatibility complex class I
(MHC-I) pathway (Burgdorf et al., 2007; Lin et al., 2008;
Amigorena and Savina, 2010). The immunogenicity of freeze-
thawed necrotic cells was assessed previously and several
studies failed to show that necrotic cells generated Ag-
specific CD8+ T cell mediated immune responses (Scheffer
et al., 2003; Bartholomae et al., 2004; Yoon et al., 2008;
Gamrekelashvili et al., 2012). To the best of our knowledge,
our study represents the first report that clearly demonstrates
enhanced immunogenicity of necrotic cells loaded with viral
antigen and used as a prophylactic vaccine. Our findings are
supported by those of a previous study, which found that
the induction of necrosis by heating the cells induced Ag-
specific T cell activation both in vitro and in vivo, using
ovalbumin as a model antigen (Gamrekelashvili et al., 2013).
That study found that inactivation of DPP-3 and TOP-1
peptidases by heating resulted in protection of their oligopeptide
substrates from degradation and accounted for the mechanism
by which heat-induced necrotic cells activated Ag-specific T
cell responses. Furthermore, in contrast to freeze-thawing, heat-
induced necrosis generates extensive antigen denaturation and
aggregation, which should result in more efficient processing and
presentation of antigens by DC.
In a natural HCV infection, since HCV is tissue tropic and
non-cytopathic, cross-presentation of viral antigens is likely
to be limited. Vaccination with necrotic cells overcomes these
limitations as it can direct the NS3 antigen into the MHC-I/cross-
presenting pathway and thus may constitute an exciting new
prophylactic vaccine.
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